Cells utilize two major modes of energy metabolism: glycolysis and oxidative phosphorylation (OXPHOS). Efforts to target metabolism in cancer have mainly focused on glycolysis due to the observation that cancer cells preferentially utilize this mode, termed the Warburg effect. However, there is renewed interest in targeting OXPHOS through its effector, the electron transport chain (ETC), primarily because of the discovery that the widely used anti-diabetic drug, metformin, lowers risk of cancer incidence in diabetes patients and kills cancer cells in vitro and in vivo through inhibiting complex I of the ETC. The ETC is composed of five complexes that work to sequentially transfer electrons in a series of redox reactions that result in the generation of ATP. As the efforts to target the ETC in cancer are relatively recent, fundamental knowledge such as the landscape of dependence on the ETC and more specifically, particular ETC complexes, across cancers remains unknown. To investigate these questions, our lab has defined the dependence on inhibition of each ETC complex across a large panel of diverse cancer cell lines. Intriguingly, cell lines respond variably to inhibition of individual ETC complexes, with complex I inhibition yielding homogeneous cell death and complex II-V inhibition causing heterogeneous cell death. We naively expected that ETC complex dependencies would correlate with each other due to the linearity of the ETC; additional preliminary data show that ATP levels remain unchanged with ETC inhibition. Taken together, these results suggest that ETC complexes may play important roles in maintaining cell viability independently of their canonical roles in OXPHOS. To that end, we performed CRISPR/Cas9 screens and metabolomics analyses to determine the non- canonical metabolic mechanisms modulating ETC complex dependences. We identified various biosynthetic metabolic pathways that modulate, and are modulated by, individual ETC complex inhibition. Of particular interest, we identified a novel synthetic lethal combination between complex III inhibition and loss of the mevalonate pathway that has promising translational potential. The mevalonate pathway synthesizes various isoprenoids, such as cholesterol and ubiquinone, and has been implicated in tumor initiation and progression; additionally, this pathway is inhibited by statin drugs, commonly used in the clinic to lower cholesterol levels. As mechanisms describing the regulation of complex III by the mevalonate pathway have not yet been elucidated, this is an interesting relationship to investigate for both basic and translational reasons. In this proposal, we will investigate the hypothesis that ubiquinone synthesis regulates the relationship between the mevalonate pathway and complex III. We will also determine if the efficacy of complex III inhibition can be enhanced by using statins in both immune-competent and immune-deficient mouse models of cancer.
We have determined that individual electron transport chain complexes are variably essential across cancer cell lines and have performed CRISPR/Cas9 screens and metabolomics to uncover the non- canonical metabolic process that modulate ETC complex sensitivities. Here, we investigate the mechanisms of regulation and translatability of a novel synthetic lethal interaction between inhibition of complex III and loss of the mevalonate pathway identified by these screens. Importantly, the aims outlined in this proposal will allow us to elucidate an important fundamental gap in biological knowledge about the interplay between ETC complexes, biosynthetic metabolism, and proliferation, as well as leverage this knowledge to investigate the clinical potential of combined complex III and mevalonate pathway inhibition in cancer.
